Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
| Status: | Completed |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/13/2018 |
| Start Date: | October 2011 |
| End Date: | October 2016 |
Phase I study of SPARC1023 alone and in combination with carboplatin
Pharmacokinetic profile and dose escalation study of SPARC1023 when administered as 30-min
infusion.
infusion.
Inclusion Criteria:
- Age ≥18 years
- ECOG Performance Status ≤ 1.
- Estimated life expectancy of at least 12-weeks;
- Measurable disease as per RECIST guideline (Version 1.1);
Exclusion Criteria:
- Any malignancy within past 5-years, except non-melanoma skin cancer, cervical
intraepithelial neoplasia, or in situ cervical cancer
- Known hypersensitivity to the study drugs
- Treatment with any anti-cancer agents within 28 days of study entry
- Presence of clinically evident active CNS metastases, including leptomeningeal
involvement, requiring steroid or radiation therapy
We found this trial at
1
site
